Anodyne Nanotech Inc
01/12/2026 | Press release | Archived content
Meet Anodyne at JPM Healthcare Week 2026
Anodyne will be attending the J.P. Morgan Healthcare Conference 2026, taking place January 12-15 in San Francisco, California. The event brings together healthcare leaders, innovators, investors, and strategic partners from across the industry to discuss the future of healthcare and emerging opportunities.
At Anodyne, we're advancing HeroPatch™, a transdermal drug delivery platform designed to enable the delivery of peptides, biologics, and nucleic acid therapies through a convenient, patient-friendly patch. Our lead program, ANN-101, is a once-weekly GLP-1 patch for obesity that demonstrates the platform's potential to transform injectable therapies into room-temperature-stable transdermal products.
Jake Lombardo (CEO) and Konstantinos Tzortzakis (CBO) will also be attending Biotech Showcase, BIO Partnering, and other events taking place throughout JPM Week. We look forward to connecting with industry leaders, sharing our recent progress, and exploring strategic partnership opportunities
Connect with Us: If you'll be attending, feel free to reach out to schedule a meeting or learn more about our work at [email protected]
Anodyne Nanotech Inc published this content on January 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 28, 2026 at 19:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]